Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production

Adrenocortical carcinoma (ACC) is an aggressive cancer with poor response to chemotherapeutic and immunotherapeutic agents. About half of ACCs produce glucocorticoids (GC), and the presence of GC excess (hypercortisolism) is correlated with decreased survival in patients with ACC. The broad immunosu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Endocr Soc
Hlavní autoři: Habra, Mouhammed Amir, Hammer, Gary D, Kebebew, Electron, Worden, Francis P, Raj, Nitya, Hallanger-Johnson, Julie E, Grauer, Andreas, Moraitis, Andreas
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2021
Témata:
Adrenal
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089943/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.188
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky